Nanosonics Limited · ASX:NAN
Nanosonics — Shareholder Meeting (November 2016)
40 slides from Nanosonics's shareholder meeting presentation, Nov 4, 2016
Slide 1: Nanosonics Limited 2016 Annual General Meeting
For personal use only Nanosonics Limited 2016 Annual General Meeting 4 November 2016
Slide 2: Nanosonics Board and Secretaries
Nanosonics Board and Secretaries For personal use only Ron Weinberger Maurie Stang David Fisher President Technology Chairman Non-Executive Director Development/Commercialisation McGregor Grant Michael Kavanagh Richard England CFO / Company Secretary CEO and Executive Director Non-Executive Director
Slide 3: Chairman's Address
For personal use only Nanosonics Limited 2016 Annual General Meeting Chairman’s Address Mr Maurie Stang
Slide 4: Financial Results
For personal use only Financial Results
Slide 5: Regional Update
For personal use only Regional Update
Slide 6: Research & Development
Research & Development For personal use only
Slide 7: Nanosonics Board and Secretaries
Nanosonics Board and Secretaries For personal use only Ron Weinberger Maurie Stang David Fisher President Technology Chairman Non-Executive Director Development/Commercialisation McGregor Grant Michael Kavanagh Richard England CFO / Company Secretary CEO and Executive Director Non-Executive Director
Slide 8: Innovation, Collaboration, Growth
nariosonics (CM testion Prevention. For Life. INNOVATION COLLABORATION GROWTH
Slide 9: CEO Address: Mr. Michael Kavanagh
For personal use only Nanosonics Limited 2016 Annual General Meeting Mr. Michael Kavanagh Chief Executive Officer & President
Slide 10: Nanosonics Senior Leadership Team
Nanosonic’s Senior Leadership Team For personal use only Dr. Ron McGregor Weinberger Dr. Steven Gerard Putt Grant President Farrugia Head of CFO / Company Technology SVP Design & Manufacturing Secretary Development/ Development & Operations Commercialisation Andrew Vincent Wang Ruth Cremin Kirste Co
Slide 11: Corporate Mission
Corporate Mission For personal use only We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovative technologies that deliver improved standards of care. 2016 Nanosonics |
Slide 12: trophon EPR
trophon EPR For personal use only trophon is the safe, versatile and simple way to high level disinfect ultrasound probes. Anything else is a compromise. Safe Versatile Simple trophon assures safety for trophon streamlines trophon makes ultrasound patient, staff and the practice workflows to probe d
Slide 13: Large market opportunity & attractive revenue model
Large market opportunity & attractive revenue model For personal use only trophon device Accessories Capital sales Global addressable installed base: ~120,000 trophon EPR units Service and Consumables maintenance contracts Recurring annuity revenue 2016 Nanosonics | 13
Slide 14: Corporate objectives
Corporate objectives For personal use only Customer Experience Establish our offerings as new standards of care globally and provide customers a convenient, seamless and consistent experience with both product and brand. Product Innovation Operational Excellence People Engagement Create and bring to
Slide 15: 2016 Highlights
2016 Highlights For personal use only Customer Experience Operational Excellence • Installed base growth of 74% in North America to • Successful first full year of North American direct over 8,700 units and 10,000 globally operations • Market expansion activities in Europe, Middle • Successful certi
Slide 16: 2016 Key Financial Results
2016 Key Financial Results For personal use only • Total sales for the year were $42.8 million, an increase of 93% on pcp. • Strong adoption of trophon continued in North America following the establishment of Nanosonics’ direct operations in 2015. • Maiden full year profit of $122,000 with $3.4 mil
Slide 17: Excellent growth momentum under new North American business model
Excellent growth momentum under new North For personal use only American business model FY15 Q3 – Announced new Quarterly Sales business model $ million FY15 Q3 / Q4 – Established North American operations and commenced building pipeline FY16 Q1 / Q2 – Direct sales momentum in North America and cont
Slide 18: Growth in Market Capitalisation
Growth in Market Capitalisation For personal use only 3 years to 2 November 2016: Up 264% 380% NAN ASX300 ASX300 Healthcare 330% 280% 230% 180% 130% 80% 01 Nov 13 26 Mar 14 18 Aug 14 08 Jan 15 01 Jun 15 19 Oct 15 11 Mar 16 04 Aug 16 1 year to 2 November 2016: Up 101% 210% NAN ASX300 ASX300 Healthcar
Slide 19: Regional Highlights
For personal use only Regional Highlights
Slide 20: Regional Highlights: North America
Regional Highlights For personal use only North America The fundamentals for adoption continued to strengthen 74% installed base growth to over 8,700 units in FY16 Sales grew a record 121% to $39.0M in North America • Successful first year of direct sales operations • trophon has now commenced in 48
Slide 21: Fundamentals for adoption continue to strengthen
Fundamentals for adoption continue to For personal use only strengthen Released a Health Advisory emphasising the need to properly maintain, clean, and disinfect or sterilize reusable medical devices1 Non compliance with infection control standards associated with medical equipment & devices is one
Slide 22: trophon breaks new ground in ultrasound probe disinfection
trophon breaks new ground in ultrasound For personal use only probe disinfection HPV accounts for > 5% cancer worldwide trophon: the only system proven & 99.7% of cervical cancer to kill cancer causing HPV “a considerable number of 2014 study showed ultrasound probes contaminated with human and disi
Slide 23: Regional Highlights Europe
Regional Highlights Europe For personal use only FY16 focus in Europe centred on market development to strengthen the fundamentals for adoption • In UK now 25 trusts with trophon. • Welsh guidelines leads to all 7 health boards RCOG World Congress 2016 adopting of trophon • New Scottish guidelines p
Slide 24: Regional Highlights: Australia/NZ and ROW
Regional Highlights For personal use only Australia/NZ • Sales growth of 11% • trophon as standard of care with >1,000 units installed and continuing to growing off a high base • Excellent demonstration of what is possible when fundamentals for adoption strong ROW • Progressed Japanese commercialisa
Slide 25: Focussed ramp up in R&D program
Focussed ramp up in R&D program For personal use only • Increased investment in R&D by 50% to $7.3 million • Strategic partnerships in place with key associations • Solid progress made on future generations of the trophon platform technology plus research on novel new solutions to meet a number of c
Slide 26: Business Outlook
For personal use only Business Outlook Positioned for ongoing growth • Fundamentals for adoption continue to strengthen • North American Business model driving growth • Growing Installed base • New supporting guidelines expected in England • Expansion into new territories being planned • Active R&D
Slide 27: Thank you
For personal use only Thank you 2016 Nanosonics | 27
Slide 28: Formal Business
For personal use only Nanosonics Limited 2016 Annual General Meeting Formal Business 2016 Nanosonics | 28
Slide 29: Resolution: Election of a Director – Maurie Stang
Resolution 1 For personal use only Election of a Director – Maurie Stang 2016 Nanosonics | 29
Slide 30: Resolution: Election of a Director – Maurie Stang
Resolution 1 For personal use only Election of a Director – Maurie Stang Resolution: That Mr Maurie Stang, who retires as a Director pursuant to the Company’s Constitution and, being eligible, offers himself for re- election, be re-elected a Director. Proxy votes received For : 159,553,698 Against :
Slide 31: Resolution: Election of a Director – Steven Sargent
Resolution 2 For personal use only Election of a Director – Steven Sargent 2016 Nanosonics | 31
Slide 32: Resolution: Election of a Director – Steven Sargent
Resolution 2 For personal use only Election of a Director – Steven Sargent Resolution: That Mr Steven Sargent, who was appointed to the Board since the 2015 AGM, retires as a Director pursuant to the Company’s Constitution and, being eligible, offers himself for election, be elected as a Director. P
Slide 33: Resolution: Election of a Director – Marie McDonald
Resolution 3 For personal use only Election of a Director – Marie McDonald 2016 Nanosonics | 33
Slide 34: Resolution: Election of a Director – Marie McDonald
Resolution 3 For personal use only Election of a Director – Marie McDonald Resolution: That Ms Marie McDonald, who will be appointed to the Board since the 2015 AGM, retires as a Director pursuant to the Company’s Constitution and, being eligible, will offer herself for election, be elected as a Dir
Slide 35: Resolution: Remuneration report
Resolution 4 For personal use only Remuneration report Resolution: That the Remuneration Report for the financial year ended 30 June 2016 be adopted. Proxy votes received Votes for : 143,057,463 Against : 736,105 Discretion : 507,468 Abstained/Excluded : 23,422,213 2016 Nanosonics | 35
Slide 36: Resolution: Performance Rights and Options to the CEO
Resolution 5 For personal use only Issue of Performance Rights and Options to the CEO and President under 2016 LTIS Resolution: That approval be given for all purposes under the Corporations Act 2001 (Cth) and the ASX Listing Rules: a) for the issue of 42,138 Performance Rights and 211,306 Options t
Slide 37: Resolution: Performance Rights and Options to President Technology
Resolution 6 For personal use only Issue of Performance Rights and Options to the President Technology Development / Commercialisation under 2016 LTIS Resolution: That approval be given for all purposes under the Corporations Act 2001 (Cth) and the ASX Listing Rules: a) for the issue of 13,445 Perfo
Slide 38: Resolution: Increase Non-Executive Directors' Remuneration
Resolution 7 For personal use only Increase the Non-Executive Directors’ Remuneration Resolution: That for the purposes of Clause 7.3 of the Company’s Constitution and ASX Listing Rule 10.17, the maximum aggregate remuneration payable to Non-Executive Directors in any financial year be increased by
Slide 39: Resolution: Adoption of Nanosonics Omnibus Equity Plan
Resolution 8 For personal use only Adoption of the Nanosonics Omnibus Equity Plan Resolution: That, for the purposes of ASX Listing Rule 7.2, Exception 9, and for all other purposes, approval be given for the Company to adopt the Nanosonics Omnibus Equity Plan (the Omnibus Plan) and for the issue of
Slide 40: Questions
For personal use only Questions